NL-OMON38947
Completed
Phase 2
A randomized, double-blind, placebo controlled multiple dose study of subcutaneous ACZ885 for the treatment of abdominal aortic aneurysm - Phase II study for the treatment of abdominal aortic aneurysm
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Abdominal aortic aneurysm
- Sponsor
- ovartis
- Enrollment
- 7
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
Trial is onging in other countries
Investigators
Eligibility Criteria
Inclusion Criteria
- •\* Male and female subjects age \*45 years of age
- •\* Infrarenal abdominal aortic aneurysm with maximum diameter:
- •\* for men \*40mm and \*50mm
- •\* for women \*38mm and \*48mm
- •\* On a stable medical regimen for at least 2 weeks prior to dosing
- •\* Have an evaluable ultrasound image at screening for thequantitative determination of the AAA size
- •\* At screening and pre\-dose on Day 1, vital signs (systolic and diastolic blood pressure and pulse rate) will be assessed in the sitting position after the subject has rested for at least three minutes.
- •Sitting vital signs should be within the following ranges:
- •oral body temperature between 35\.0\-37\.5°C
- •systolic blood pressure, 90\-170 mm Hg
Exclusion Criteria
- •\*Known diabetes by medical history, a HbA1c of \*6\.5% at screening, or on an active diabetic medical regimen
- •\* Women of child bearing potential unless using effective methods of contraception
- •\* Subjects on the following medications:
- •1\) Chronic systemic steroid treatment or other systemic immunosuppression. Use oftopical, ophthalmic or inhaled steroids at doses not considered to have systemic effects is allowed. Temporary use of steroids (e.g., for asthma exacerbations) are allowed if last steroid use is more than 1 month prior to screening and the anticipated frequency of requiring such steroids are less than once per year.
- •2\) Any biologic drugs targeting the immune system, e.g., TNF blockers, anakinra, rituximab, abatacept, tocilizumab. Any previous history of the use of such biologics is also an excluded.
- •\* Presence of a non\-healing wound or infection, including active urinary tract infections, or any recent process requiring significant tissue healing per investigator assessment. Other active infections
- •within 2 weeks will be excluded.
- •\* Previous infra\-renal aortic surgery
- •\* Known aortic dissection
- •\* Subjects should exhibit no signs of clinically concerning unstable acceleration of AAA size or growth rate at the time of enrollment per investigator assessment
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis PatientsNL-OMON46238Savara ApS9
Completed
Not Applicable
A randomized, double-blind, placebo-controlled study to investigate the effects of an 8-week recombinant human erythropoietin (NeoRecormon) treatment on well-trained cyclists and their cycling performance.FietsprestatieCycling performanceslow cyclingNL-OMON44014Centre for Human Drug Research48
Completed
Phase 2
A Randomized, Double-Blind, Placebo Controlled Study of COR388 HCl in Subjects with Alzheimer*s DiseaseAlzheimer's diseasedementianeurodegenerative disease10012272NL-OMON54863Cortexyme, Inc.31
Completed
Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727/Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapyfamilial hypercholesterolemiainherited hyperlipidemia100274241001331710003216NL-OMON39858Sanofi-aventis18
Completed
Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to evaluate the Efficacy and Safety of SAR236553 (REGN727) in Patients With Heterozygous Familial Hypercholesterolemia and LDL-C higher or equal to 160mg/dL with Their Lipid-Modifying Therapyfamilial hypercholesterolemiainherited hyperlipidemia100274241001331710003216NL-OMON39914Sanofi-aventis11